Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
REGULATORY
Council on “Clinical Innovation Network” Holds 1st Meeting, 7 Working Groups to Design Registries
The health ministry’s council to improve the environment for clinical development held its first meeting on August 20 to discuss the creation of what is called the “clinical innovation network,” a patient-registry-based infrastructure aimed at facilitating clinical trials in Japan.…
To read the full story
Related Article
- MHLW to Draw Up Guidelines on Registry Data Use for Submissions: Clinical Innovation Network Initiative
March 15, 2019
- Centralized Support Unit Needed for “Clinical Innovation Network”: JPMA’s Teshirogi
April 8, 2016
- MHLW Seeks 30.7 Trillion Yen in FY2016 Budget, 104.3 Billion for Drug, Healthcare Initiatives
August 27, 2015
- MHLW to Seek FY2016 Budgets for Genomic Data Collection, Registry-Based Trial Platform
August 20, 2015
- NCC Eyes Trial Enrollment of 150 Rare Cancer Patients under Registry Initiative
July 3, 2015
- Govt OKs Economic Growth Strategy, Regulatory Reform Plan
July 1, 2015
- Japan Cabinet OKs Fiscal Policy Guidelines, Marking Dawn of “80% Generic” Era
July 1, 2015
- LDP Weighs Clinical Development Infrastructure Utilizing Patient Registry
April 24, 2015
REGULATORY
- Japan Officially Eases Trial Recruitment Rules; Industry Welcomes Move
April 1, 2026
- MHLW Updates Q&A on Use of Registry Data in Drug Applications
April 1, 2026
- Japan Panel Designates Two Ebola Therapies for Early Approval Pathway
April 1, 2026
- MHLW, METI Launch Joint Task Force to Safeguard Medical Supply Chains
April 1, 2026
- Japan Urges Priority Supply of Petroleum-Based Materials for Medical Devices
March 31, 2026
Japan will overhaul its R&D tax credit regime in its FY2026 reform, introducing a new strategic category alongside existing frameworks.…
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…